Bristol-Myers Squibb Pharmaceuticals Ltd

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH , UK
Telephone: +44 (0)1895 523 000
Fax: +44 (0)1895 523 010
Medical Information Direct Line: +44 (0)1895 523 740
Medical Information e-mail: medical.information@bms.com
Medical Information Fax: +44 (0)1895 523 677
Patient Information Leaflet last updated on the eMC: 28/08/2009
PIL Baraclude 0.5 mg and 1.0 mg film coated tablets and 0.05mg/ml oral solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 28/08/2009 and displayed until Current
Reasons for adding or updating:
  • Change of inactive ingredient
  • Change to date of revision
  • Change to side-effects
Updated on 19/09/2008 and displayed until 28/08/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Introduction of new pack/pack size
Updated on 08/01/2008 and displayed until 19/09/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 05/06/2007 and displayed until 08/01/2008
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 05/06/2007 and displayed until 05/06/2007
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   entecavir


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk